79.42
前日終値:
$80.83
開ける:
$81
24時間の取引高:
6.32M
Relative Volume:
0.85
時価総額:
$100.82B
収益:
$393.94B
当期純損益:
$428.00M
株価収益率:
207.58
EPS:
0.3826
ネットキャッシュフロー:
$6.29B
1週間 パフォーマンス:
+5.01%
1か月 パフォーマンス:
-1.05%
6か月 パフォーマンス:
+19.70%
1年 パフォーマンス:
+60.19%
Cvs Health Corp Stock (CVS) Company Profile
CVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CVS
Cvs Health Corp
|
79.42 | 102.61B | 393.94B | 428.00M | 6.29B | 0.3826 |
|
UNH
Unitedhealth Group Inc
|
341.84 | 305.02B | 435.16B | 18.37B | 17.37B | 19.16 |
|
ELV
Elevance Health Inc
|
359.07 | 80.05B | 194.82B | 5.53B | 3.77B | 24.45 |
|
CI
Cigna Group
|
274.70 | 72.73B | 268.22B | 6.55B | 7.44B | 22.67 |
|
HUM
Humana Inc
|
268.45 | 32.05B | 123.11B | 1.58B | 2.44B | 13.03 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-14 | 開始されました | Goldman | Buy |
| 2025-08-18 | アップグレード | UBS | Neutral → Buy |
| 2025-08-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | アップグレード | Edward Jones | Hold → Buy |
| 2024-12-03 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-11-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-10-04 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-30 | 開始されました | Robert W. Baird | Neutral |
| 2024-05-07 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-05-02 | ダウングレード | UBS | Buy → Neutral |
| 2024-05-01 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | 開始されました | Barclays | Equal Weight |
| 2024-02-26 | 開始されました | Leerink Partners | Outperform |
| 2023-12-22 | 開始されました | HSBC Securities | Buy |
| 2023-09-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-09-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | ダウングレード | Edward Jones | Buy → Hold |
| 2023-05-26 | 開始されました | Piper Sandler | Overweight |
| 2023-04-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-11-23 | 再開されました | Morgan Stanley | Overweight |
| 2022-06-17 | 開始されました | Loop Capital | Buy |
| 2022-05-27 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-02-11 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | 開始されました | Goldman | Buy |
| 2021-12-01 | 開始されました | Seaport Research Partners | Buy |
| 2021-05-19 | 開始されました | Wells Fargo | Equal Weight |
| 2021-03-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-01-08 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-17 | 開始されました | Piper Sandler | Overweight |
| 2020-07-01 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-05-14 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-09-12 | 開始されました | Deutsche Bank | Buy |
| 2019-06-05 | アップグレード | Standpoint Research | Hold → Buy |
| 2019-04-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | 開始されました | Guggenheim | Buy |
| 2019-04-15 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2019-04-10 | 繰り返されました | BofA/Merrill | Buy |
| 2019-03-13 | 開始されました | Bernstein | Outperform |
| 2019-02-20 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | 開始されました | UBS | Buy |
| 2018-12-18 | 開始されました | Barclays | Overweight |
| 2018-11-29 | 再開されました | Goldman | Neutral |
| 2018-11-28 | 開始されました | Evercore ISI | Outperform |
| 2018-10-26 | 再開されました | Wolfe Research | Peer Perform |
| 2018-07-09 | アップグレード | Citigroup | Neutral → Buy |
| 2018-02-27 | 再開されました | BofA/Merrill | Buy |
| 2018-02-13 | 繰り返されました | Citigroup | Neutral |
すべてを表示
Cvs Health Corp (CVS) 最新ニュース
Putting pharmacy education within reach - CVS Health
CVS: Bernstein Raises Price Target for CVS Health to $87 | CVS S - GuruFocus
Bernstein raises CVS Health stock price target to $87 on Aetna growth potential - Investing.com
CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak - Financial Times
Jim Cramer on CVS: "This Stock Has Become the Best Performer in the Healthcare Sector" - Finviz
Jim Cramer on CVS: “This Stock Has Become the Best Performer in the Healthcare Sector” - Insider Monkey
CVS Health (CVS) Receives Analyst Price Target Upgrade to $98 | - GuruFocus
CVS Health (CVS) Sees Analyst Rating Update from Piper Sandler | - GuruFocus
CVS Health Is Seeing Margin And App Momentum, Analyst Highlights - Benzinga
CVS Health Targets Steady Gains With A Revamped Game Plan - Finimize
CVS Health Stock (CVS) Opinions on 2025 Guidance Update - Quiver Quantitative
CVS Health (CVS) Analysts Maintain Overweight, Raise Price Targe - GuruFocus
UBS Maintains Buy Rating, Raises Price Target for CVS to $97 | C - GuruFocus
CVS Health Raises Its Long-Term Outlook And Stock Follows Suit - Finimize
CVS forecasts 2026 profit higher than Wall Street estimates - Providence Business News
CVS Health Corporation (CVS) Sees Higher Price Target Despite PBM Pressures - Insider Monkey
Mizuho Raises Price Target for CVS Health (CVS) to $95.00 | CVS Stock News - GuruFocus
CVS Health (CVS) Receives Price Target Increase from Morgan Stan - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on CVS Health stock - Investing.com
Piper Sandler raises CVS Health stock price target to $101 on growth outlook - Investing.com
CVS (CVS) Analyst Rating Update: Baird Raises Price Target to $9 - GuruFocus
Intact Investment Management Inc. Sells 20,100 Shares of CVS Health Corporation $CVS - MarketBeat
Morgan Stanley raises CVS Health stock price target to $93 on turnaround - Investing.com
RBC Capital reiterates Outperform rating on CVS Health stock with $93 target - Investing.com
Truist Securities raises CVS Health stock price target to $98 on upbeat outlook - Investing.com
3 Reasons CVS is Risky and 1 Stock to Buy Instead - Finviz
CVS Health stock price target raised to $97 from $96 at UBS - Investing.com
BofA Securities reiterates Buy rating on CVS Health stock with $100 target - Investing.com
CVS Health stock price target raised to $95 by Mizuho on positive outlook - Investing.com
TD Cowen raises CVS Health stock price target to $105 on Medicare Advantage recovery - Investing.com
How Recent Shifts Are Rewriting the Story for CVS Health - Yahoo Finance
CVS raises profit forecast as turnaround plan takes effect - Honolulu Star-Advertiser
CVS forecasts 2026 profit above estimates as turnaround plan takes effect - Denver Gazette
CVS boosts profit outlook in sign of momentum as 2026 nears - The Boston Globe
CVS Health Hikes Its Outlook, and Says It Plans to Roll Out AI Platform - Investopedia
CVS Raises Profit Outlook in Sign of Momentum for 2026 - Transport Topics
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Is It Time to Bet on CVS Health? - StocksToTrade
CVS Health: Investor Day Targets Set Attractive Baseline For 2026 (CVS) - Seeking Alpha
CVS Forecasts 2026 Revenue Short of Wall Street Estimates - Bloomberg.com
Why CVS Health (CVS) Stock Is Up Today - Finviz
CVS Investor Day Highlights Major Growth AheadBullish Chart Into 2026 (NYSE:CVS) - Seeking Alpha
CVS Health raises guidance, predicts strong 2026 - Modern Healthcare
CVS Stock Rises Amid Positive Market Movement - GuruFocus
CVS Health lifts full-year guidance during investor event - Proactive financial news
Why Is CVS Health Stock Surging Today?CVS Health (NYSE:CVS) - Benzinga
CVS lifts outlook, Home Depot remains cautious, AutoZone earnings - Yahoo! Finance Canada
CVS Health Lifts Outlook And Sets Sights On AI Innovation - Finimize
CVS forecasts 2026 profit above estimates as turnaround plan takes effect By Reuters - Investing.com
CVS Health Corporation Provides Goodwill Impairment Guidance for the Year Ending December 31, 2025 - marketscreener.com
CVS Projects Mid-Teens EPS Growth through 2028 - GuruFocus
Cvs Health Corp (CVS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):